Aethlon Medical Inc. is hoping its first shipment of its Hemopurifier to the United States will help treat Ebola patients.
The Aethlon Hemopurifier targets the rapid elimination of viruses and tumor-secreted exosomes that promote cancer progression, and has also been shown to eliminate the Ebola virus as evidenced by a recent report involving a Ugandan doctor.
Aethlon shipped four units to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha and provided onsite training to NMC personnel. Aethlon sent the units on a humanitarian basis and as such, will not turn a profit.
The Nebraska Biocontainment Unit, which has treated three Ebola patients during the current outbreak, was designed to treat those affected by bioterrorism or extreme infections, such as Ebola. It is the largest facility of its kind in the U.S.
In the United States, Hemopurifier therapy is available to treat Ebola-affected individuals via the U.S. Food and Drug Administration's (FDA) expanded access "emergency use" provisions during life-threatening circumstances where other treatment is not available. Currently, no antiviral therapy or vaccine has been effective against Ebola.
Aethlon will soon begin the first clinical Hemopurifier studies in the U.S. The study will contribute safety data to advance the device as a combatant against bioterror and pandemic threats, including Ebola, Hepatitis C and HIV.